Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

Aglatimagene is an investigational therapy that uses a modified virus to deliver a cancer-fighting gene into tumor cells.

Men given two larger doses of radiation had about the same side effects as others treated with the standard five-dose course, researchers reported Sunday at a meeting of the European Society for ...

Advances in radiotherapy are rapidly transforming how prostate cancer is treated, offering patients more precise, less invasive options that can fit more easily around everyday life ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...